ACTH tail fragment (18-39): research tool

What this is

ACTH (adrenocorticotropic hormone, also called corticotropin) is a 39-amino-acid peptide secreted by the anterior pituitary gland that acts on the adrenal cortex to trigger the synthesis and release of cortisol. It is one of the most thoroughly characterized peptides in clinical endocrinology. The stored sequence for this card (RPVKVYPNGAEDESAEAFPLEF) represents residues 18–39 of the full 39-residue hormone — the C-terminal portion, which does not carry MC2R-binding activity; the biologically active N-terminus (residues 1–24) is the basis for cosyntropin, the synthetic diagnostic fragment used in clinical medicine.

Two synthetic forms are used in medicine. Cosyntropin (also known as tetracosactide or tetracosactrin) is a synthetic 24-amino-acid N-terminal fragment that retains full MC2R-binding activity and is used almost exclusively as a diagnostic agent — the cosyntropin stimulation test is the reference standard for evaluating adrenal reserve. Repository corticotropin injection (Acthar Gel) is a long-acting intramuscular or subcutaneous depot of full-length porcine-derived corticotropin in a gelatin vehicle, FDA-approved for infantile spasms, acute multiple sclerosis exacerbations, nephrotic syndrome, and a cluster of rheumatologic conditions.

ACTH is not used in wellness, biohacking, or compounded-peptide contexts. It is a prescription-only hormone administered or supervised by endocrinologists, neurologists, rheumatologists, or nephrologists depending on the indication.

History

ACTH was isolated in the early 1950s by several groups working on pituitary chemistry, most notably Choh Hao Li at UC Berkeley, who purified and characterized its adrenocorticotropic activity. Therapeutic use followed almost immediately: Philip Hench at the Mayo Clinic had demonstrated in 1948 that cortisone produced dramatic short-term improvement in rheumatoid arthritis, and ACTH became a natural companion, used either to test adrenal function or to drive endogenous cortisol release. The synthetic 1–24 fragment cosyntropin was developed in the 1960s once the active N-terminus was characterized; it quickly displaced full-length ACTH for diagnostic testing because it was cheaper, less antigenic, and functionally equivalent at MC2R. Repository corticotropin injection (later marketed as Acthar Gel) was introduced as a long-acting depot and gained FDA approval for a broad list of conditions in the 1950s under a looser regulatory regime than modern NDAs require. The drug's subsequent commercial story — low-cost obscurity through the 1990s followed by repeated ownership changes and steep price increases in the 2010s — became a widely cited case study in legacy-drug pricing. Clinically, infantile spasms remain the major indication where ACTH holds standard-of-care status, as reviewed by Harno and colleagues in their comprehensive analysis of POMC processing and its downstream peptides (Physiological Reviews, 2018).

What it does

ACTH tells the adrenal glands — two small glands that sit on top of the kidneys — to produce cortisol, the body's primary stress hormone. Synthetic versions serve two distinct purposes in medicine: cosyntropin is given as a single injection to check whether the adrenal glands can respond normally (a test for adrenal insufficiency), while repository corticotropin (Acthar Gel) is given as a therapeutic course in certain inflammatory and neurological conditions. In infantile spasms, ACTH is a recognized first-line treatment. In multiple sclerosis acute relapses and some inflammatory conditions such as nephrotic syndrome, Acthar Gel has an approved role, though whether it adds meaningful benefit beyond synthetic corticosteroids given at equivalent dose remains debated.

ACTH also shares structural features with alpha-melanocyte-stimulating hormone — both are derived from the same precursor protein POMC — and has modest binding affinity for melanocortin receptors beyond MC2R. This overlap has prompted investigation into whether ACTH (and repository corticotropin specifically) exerts anti-inflammatory effects through MC1R or MC3R signaling on immune cells that are partially separate from cortisol-driven immunosuppression, a hypothesis reviewed in the context of melanocortin receptor pharmacology by Hruby and colleagues (Expert Opinion on Drug Discovery, 2011) and the broader POMC system by Yeo and colleagues (Molecular Metabolism, 2021).

Evidence

• Human: Strong for cosyntropin diagnostic testing, which has multi-decade clinical validation as the reference adrenal stimulation test. Acthar Gel has RCT evidence supporting its use in infantile spasms. Evidence for other approved indications — acute MS exacerbations, nephrotic syndrome, and rheumatologic conditions — ranges from historical case series to mixed RCTs; incremental benefit over high-dose synthetic glucocorticoids is not established for most of those indications.
• Animal: Extensive and largely historical. ACTH physiology was characterized across large numbers of animal experiments from the 1950s through the 1980s. More recent preclinical work has focused on MC1R/MC3R anti-inflammatory signaling, examined in the context of melanocortin receptor structure and function by Fridmanis and colleagues (Frontiers in Endocrinology, 2017).
• In vitro: Strong. MC2R pharmacology and the melanocortin receptor accessory protein (MRAP) — which is required for MC2R surface expression and ACTH responsiveness — are well-characterized, as reviewed by Hinkle and colleagues (Molecular and Cellular Endocrinology, 2009). The cAMP/PKA/StAR steroidogenic cascade is among the best-characterized endocrine signaling pathways in the field.

Known effects

• Cortisol stimulation — MC2R-mediated; basis for both diagnostic and therapeutic use; FDA-approved
• Infantile spasms (West syndrome) treatment — FDA-approved; RCT evidence supports ACTH as a standard-of-care first-line therapy
• Acute MS relapse acceleration of recovery — FDA-approved (Acthar Gel); RCT and historical data; incremental benefit over high-dose synthetic glucocorticoids not established
• Nephrotic syndrome and rheumatologic conditions — FDA-approved (Acthar Gel); historical approvals; evidence strength varies by specific indication
• Adrenocortical hyperplasia — occurs with chronic ACTH stimulation; direct consequence of sustained MC2R activation
• MC1R/MC3R anti-inflammatory signaling (hypothesized) — preclinical evidence; clinical significance at therapeutic doses unresolved

Safety signals

Safety signals for ACTH derive almost entirely from its glucocorticoid downstream effect — sustained MC2R activation raises cortisol, and the consequences track closely with those of systemic corticosteroid therapy.

Established signals (approved label): Fluid retention and peripheral edema; hyperglycemia and glucose intolerance (cortisol-driven, relevant in patients with metabolic risk); hypertension (from mineralocorticoid and glucocorticoid effects); Cushingoid features including moon face, central weight gain, and skin thinning with prolonged exposure; mood changes, insomnia, irritability, and rarely psychosis; hypokalemia (compounded by concurrent potassium-depleting diuretics); injection-site reactions; HPA-axis suppression after prolonged courses, requiring tapering and potentially stress-dose steroid coverage during recovery; hypersensitivity reactions including anaphylaxis, particularly with porcine-derived repository formulations; blunted response to live-virus vaccination during and after high-dose courses; worsening of active systemic infections through immunosuppressive cortisol elevation.

Key label exclusions: Known hypersensitivity to ACTH, cosyntropin, or repository corticotropin components; active systemic fungal infections; ocular herpes simplex; relative contraindications shared with systemic glucocorticoid therapy (scleroderma, osteoporosis, uncontrolled heart failure, uncontrolled hypertension, active peptic ulcer disease); recent live-virus vaccination. Primary adrenocortical insufficiency is a contraindication for therapeutic Acthar Gel use, but is the reason the cosyntropin diagnostic test is performed.

Unresolved: Long-term developmental and endocrine consequences of early-life high-dose ACTH exposure in infantile-spasms cohorts are not fully characterized.

Regulatory status

• US: Prescription-only FDA-approved medication. Cosyntropin is approved for adrenal stimulation testing. Acthar Gel (repository corticotropin injection) is approved for infantile spasms, acute MS exacerbations, nephrotic syndrome, and a cluster of rheumatologic indications. Not available over the counter; not part of the compounded-peptide ecosystem.
• EU / UK / Canada / Australia / Japan: Cosyntropin (sold as Synacthen, tetracosactide, or tetracosactrin) is an approved prescription agent across major markets. Full-length ACTH and repository formulations have variable international availability; Acthar Gel itself is largely a US market phenomenon.
• WADA: Prohibited. Corticotropins fall under WADA S9 (Glucocorticoids), which covers agents that stimulate endogenous glucocorticoid production. Tetracosactide (cosyntropin) is named specifically in WADA technical documents. Therapeutic use exemptions are required for documented medical need.

Mechanism

ACTH is cleaved from the larger precursor proopiomelanocortin (POMC) in corticotroph cells of the anterior pituitary, a processing step reviewed comprehensively by Harno and colleagues (Physiological Reviews, 2018). Its primary mechanism is agonist binding to the melanocortin-2 receptor (MC2R), a Gs-coupled receptor expressed predominantly on adrenocortical cells of the zona fasciculata. Uniquely among the five melanocortin receptors, MC2R requires the accessory protein MRAP for functional surface expression and ACTH responsiveness, a structural requirement characterized by Hinkle and colleagues (Molecular and Cellular Endocrinology, 2009). The selectivity determinants underlying why MC2R responds to ACTH but not to shorter melanocortin peptides have been examined at the molecular level by Fridmanis and colleagues (Frontiers in Endocrinology, 2017).

MC2R activation raises intracellular cAMP, activating protein kinase A (PKA), which phosphorylates and activates the steroidogenic acute regulatory protein (StAR). StAR shuttles cholesterol into the mitochondria — the rate-limiting step of steroidogenesis — driving synthesis of cortisol and, in smaller amounts, aldosterone (zona glomerulosa) and adrenal androgens (zona reticularis). Chronic ACTH stimulation causes adrenocortical hyperplasia. Because ACTH shares its first 13 amino acids with alpha-melanocyte-stimulating hormone and retains modest affinity for MC1R, MC3R, and MC5R, a secondary hypothesized mechanism proposes MC1R-mediated anti-inflammatory signaling on leukocytes that is partially independent of the cortisol-driven pathway — a rationale cited by Acthar Gel advocates to explain potential clinical differences from synthetic glucocorticoids. Preclinical evidence supports MC1R/MC3R involvement in immune modulation within the broader melanocortin pathway (Yeo et al., Molecular Metabolism, 2021); whether this produces clinically distinguishable therapeutic benefit at therapeutic doses is unresolved.

Myths and misconceptions

• "ACTH is a biohacker peptide useful for energy, cortisol support, or anti-aging." No. ACTH drives cortisol release — sustained cortisol elevation is catabolic, immunosuppressive, and worsens body composition, glucose control, and sleep. ACTH does not appear on reputable compounded-peptide formularies and has no plausible self-administered use case.
• "Acthar Gel works meaningfully differently from prednisone or methylprednisolone because it is 'natural.'" Most of Acthar Gel's clinical effect in inflammatory disease is explained by cortisol release driven by MC2R activation — pharmacologically analogous to administering an equivalent synthetic glucocorticoid. A hypothesized additional contribution from MC1R/MC3R signaling exists in preclinical work, but whether it produces clinically distinguishable effects at therapeutic doses is unresolved, and price-differential justification relative to synthetic steroids is not supported by clear head-to-head superiority evidence in most approved indications.
• "A normal cosyntropin stimulation test rules out all adrenal insufficiency." The standard 250 mcg test is sensitive for primary adrenal insufficiency but can miss partial secondary (pituitary-origin) insufficiency, because it supplies a supraphysiologic ACTH stimulus. The low-dose 1 mcg test or insulin tolerance test may be needed to characterize HPA-axis dysfunction in suspected central insufficiency.
• "Cosyntropin is a different drug from ACTH." Cosyntropin is a synthetic peptide comprising the first 24 amino acids of ACTH. It binds the same MC2R receptor and triggers the same adrenal response. The truncation removes the immunogenic C-terminal region without affecting MC2R-binding determinants, all of which are located in the N-terminus.
• "ACTH is safe for long-term use because it is an endogenous hormone." Chronic supraphysiologic ACTH exposure produces the full Cushingoid side-effect profile — central weight gain, skin thinning, osteoporosis, hyperglycemia, hypertension, mood changes, and adrenal suppression on withdrawal. Endogenous origin does not confer favorable chronic-exposure biology; the sustained cortisol elevation and its consequences are the same whether the driver is exogenous ACTH or a synthetic glucocorticoid.

Open questions

• Acthar Gel vs synthetic glucocorticoids — clinical equivalence: Whether repository corticotropin's hypothesized MC1R/MC3R-mediated anti-inflammatory effects produce clinically meaningful benefit beyond what equivalent glucocorticoid exposure provides is the central unresolved question for most non-infantile-spasms approved indications. Rigorous head-to-head superiority trials are largely absent.
• Cosyntropin test cut-off thresholds with modern assays: Historical peak-cortisol thresholds derived from older polyclonal immunoassays may not apply to newer immunoassay and LC-MS/MS platforms; optimal contemporary cut-offs remain debated, particularly in borderline or central adrenal insufficiency cases.
• Comparative effectiveness in infantile spasms: Both ACTH and high-dose oral prednisolone have strong individual RCT support for infantile spasms, but head-to-head long-term developmental outcome data is incomplete.
• Long-term developmental consequences of early-life ACTH exposure: Long-term endocrine and neurodevelopmental outcomes in infantile-spasms cohorts treated with high-dose ACTH protocols are not fully characterized.
• Selective melanocortin receptor agonists as successors: If the MC1R/MC3R anti-inflammatory mechanism is real and clinically separable from glucocorticoid toxicity, targeted selective agonists could in principle deliver anti-inflammatory benefit with a reduced adverse-effect burden — an area of ongoing investigation highlighted by Hruby and colleagues (Expert Opinion on Drug Discovery, 2011).
• Pharmacoeconomic justification for Acthar Gel: The price differential between Acthar Gel and inexpensive synthetic glucocorticoids has generated legal and regulatory scrutiny, but rigorous comparative effectiveness trials resolving the question for most indications outside infantile spasms remain scarce.

Related peptides

• Alpha-MSH — shares the first 13 amino acids with ACTH and is also cleaved from POMC; acts at MC1R rather than MC2R, driving pigmentation and anti-inflammatory effects rather than cortisol release
• CLIP (Corticotropin-like intermediate lobe peptide) — derived from the same ACTH 18–39 region as the sequence stored in this card; produced by tissue-specific processing of POMC in the intermediate pituitary lobe and studied across vertebrate species including lungfish (Dores et al., General and Comparative Endocrinology, 1990)